AntiInfectiveMeds
Since 2010
| Quantity | Price per tablet | You save | Total price | |
|---|---|---|---|---|
| 30 | £3.04 | - | £91.12 | |
| 60 | £2.27 | £45.93 | £136.31 | |
| 90 | £2.02 | £91.12 | £182.24 | |
| 120 | £1.90 | £136.31 | £228.17 | |
| 180 | £1.77 | £227.43 | £319.28 | |
| 270 | £1.69 | £362.99 | £457.07 |
Your order is carefully packed and is dispatched within 24 hours. Here is what a typical package looks like.
Sized like a regular personal letter (approximately 24x11x0.7 cm), with no indication of what is inside.
| Delivery Method | Estimated delivery |
|---|---|
| Express Free for orders over £222.24 | Estimated delivery to the UK: 4-7 days |
| Standard Free for orders over £148.16 | Estimated delivery to the UK: 14-21 days |
Terbinafine is a systemic (oral) allylamine antifungal medicine that inhibits squalene epoxidase. This blocks ergosterol production and causes squalene to build up inside the fungal cell, leading to fungal cell death. Terbinafine (Lamisil) 250 mg tablets are used to treat onychomycosis of the toenail or fingernail caused by dermatophytes.
Terbinafine (Lamisil) 250 mg tablets are a synthetic allylamine antifungal, structurally similar to naftifine.
Terbinafine (Lamisil) 250 mg tablets are well absorbed (>70%), but bioavailability is about 40% because of first-pass metabolism. In plasma, more than 99% of terbinafine is bound to plasma proteins. The effective half-life is about 36 hours; a terminal half-life of 200 to 400 hours may reflect slow elimination from tissues such as the skin and fat. Terbinafine is distributed into the sebum and skin.
LAMISIL Tablets are contraindicated in patients with chronic or active liver disease. Use has not been studied adequately in patients with renal impairment (creatinine clearance ≤ 50 mL/min). Rifampicin increases terbinafine clearance and cimetidine decreases terbinafine clearance. The medicine is generally well tolerated, but rare serious side effects can include hepatotoxicity, severe neutropenia, Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious skin reactions.
Available data in humans are insufficient to assess a drug-related risk in pregnancy; because treatment of onychomycosis can usually be postponed, discuss use during pregnancy with a healthcare professional.
Terbinafine (Lamisil) 250 mg is taken as one 250 mg tablet once daily. Fingernail onychomycosis: 6 weeks. Toenail onychomycosis: 12 weeks. The best clinical effect is often seen several months after mycological cure and completion of treatment, as healthy nail grows out. In the UK, oral terbinafine tablets are licensed for onychomycosis; use for other fungal infections may be outside the licensed indications and should be guided by a healthcare professional.
Terbinafine is taken by mouth to treat dermatophyte infections of the toenail or fingernail (onychomycosis, tinea unguium) caused by susceptible fungi. Before starting oral terbinafine, appropriate nail samples should be taken for microbiological tests (for example, potassium hydroxide [KOH] preparation, fungal culture or nail biopsy) to confirm the diagnosis of onychomycosis. The best clinical effect of terbinafine in the treatment of onychomycosis is seen several months after mycological cure and completion of treatment, and reflects the time needed for healthy nail to grow out.
Because terbinafine is highly lipophilic and keratophilic, it reaches high concentrations in the stratum corneum, sebum, hair, and the nail matrix, bed and plate, and remains in these tissues for several weeks to months after the medicine is stopped. Toenail infections generally need longer treatment with terbinafine than fingernail infections.
The effectiveness of terbinafine has been established in uncontrolled studies and in placebo-controlled or active-comparator studies in patients with toenail or fingernail onychomycosis. In these studies, patients were assessed for mycological cure (no fungus seen in lesion scrapings prepared with potassium hydroxide, and negative culture of lesion scrapings), effective treatment (mycological cure plus either no nail involvement or more than 5 mm of unaffected new nail growth), or mycological and clinical cure (no nail involvement). Terbinafine has been shown to be active against most strains of Trichophyton rubrum and T. mentagrophytes both in vitro and in clinical nail infections. Although terbinafine is active in vitro against most strains of Epidermophyton floccosum, Candida albicans and Scopulariopsis brevicaulis, the effectiveness of the medicine in treating onychomycosis caused by these organisms has not yet been established in controlled clinical studies.
In toenail studies, 12 weeks of oral terbinafine 250 mg once daily was more effective than placebo or itraconazole 200 mg once daily, and 16 weeks of oral terbinafine at this dose was more effective than up to 52 weeks of oral griseofulvin 500 mg once daily. In these studies, 70-88% of patients achieved mycological cure, 59% achieved effective treatment, and 38-57% achieved mycological and clinical cure when assessed 36-48 weeks after completing terbinafine treatment; the clinical relapse rate was about 15% in those assessed at least 6 months after clinical cure and at least 1 year after completing terbinafine treatment.
In a study comparing 4 months of continuous (250 mg once daily) or intermittent (500 mg once daily for 1 week each month) oral terbinafine with intermittent (400 mg once daily for 1 week each month) oral itraconazole, there was a trend in favour of continuous terbinafine therapy, but there were no statistically significant differences in cure rates between the regimens. In a study comparing treatment durations of 6, 12 and 24 weeks in patients with toenail infections, mycological cure rates were substantially higher with the 12- and 24-week regimens than with the 6-week regimen, but the 24-week regimen was not substantially more effective than the 12-week regimen. However, some patients who do not respond to an initial 12-week course of terbinafine may respond to a second course.
In fingernail studies, 75% of patients achieved effective treatment, and 59-90% achieved mycological and clinical cure when assessed 18-42 weeks after completing treatment with oral terbinafine 250 mg once daily for 6 weeks. Extending terbinafine treatment to 12 weeks in patients with fingernail infections does not appear to improve response substantially. In one study of patients with fingernail onychomycosis who received oral terbinafine 250 mg once daily for 2 or 4 weeks, 65% had mycological and clinical cure 6 months after treatment ended; the cure rate in those who received only 2 weeks of treatment was 45%.
However, liver failure, sometimes leading to death or liver transplant, has occurred rarely in patients with or without pre-existing liver disease who were receiving terbinafine for the treatment of onychomycosis. Before starting oral terbinafine, patients should be assessed for liver disease; checking serum ALT (SGPT) and AST (SGOT) before treatment is advised for all patients.
Terbinafine should be stopped if biochemical or clinical signs of liver injury develop during treatment. Patients should be told to report any signs or symptoms of liver problems, such as persistent nausea, loss of appetite, fatigue, vomiting, pain in the upper right side of the abdomen, jaundice, dark urine or pale stools. Patients with these signs or symptoms should stop terbinafine and have their liver function checked straight away.
In the UK, terbinafine tablets are licensed for onychomycosis; use for other fungal infections may be outside the licensed indications and should be directed by a healthcare professional. The safety and effectiveness of LAMISIL Tablets have not been established in paediatric patients.
Taste disturbance is a rare side effect of terbinafine. It is usually reversible, with a median time to recovery of 42 days. However, prolonged or persistent taste disturbances have been reported.
Pancytopenia has been reported.
Neutropenia has been reported in patients taking terbinafine.
Thrombocytopenia has been attributed to terbinafine.
Minor abnormalities in liver function tests have been reported in patients taking oral terbinafine. Terbinafine can cause hepatitis, and rare cases of liver failure have been reported.
Skin side effects have been reported in patients taking terbinafine. Most of these reactions are mild to moderate macular rashes.
Generalised rashes, fixed drug eruptions, toxic epidermolysis and erythema exudativum multiforme have all been reported in association with terbinafine.
Store below 25°C (77°F) in a tightly closed container. Protect from light.
My Lamisil order to Newcastle upon Tyne has been dispatched. Does that mean it should arrive tomorrow?
Not necessarily. Dispatch means the order has been sent, while delivery is a separate step: Express delivery is usually 4-7 days and includes tracking, whereas Standard delivery is typically 14-21 days without tracking.
Before I place an order from Bristol, can I check whether Lamisil tablets can be delivered to my postcode?
Yes. Enter your Bristol postcode and delivery address at checkout before payment to see the delivery options available for that destination.
I'm in Belfast. Can I confirm whether the tablets can be delivered to my address in Northern Ireland before I pay?
Yes. Add your Belfast delivery address at checkout to check the options shown for your destination before completing payment.
My parcel arrived in Southampton after heavy rain and the outer packaging feels damp. Can I still use the tablets?
Check that the original tablet packaging is dry, intact and labelled correctly. If a blister, container or tablets are wet, damaged or otherwise compromised, do not use them until the product condition has been checked.
My 10-year-old has been diagnosed with a fungal scalp infection. Are these 250 mg terbinafine tablets suitable for children?
Terbinafine can be prescribed for children aged 1 year and over for selected fungal infections, but the dose is based on the child's age and weight. A 250 mg tablet should only be used when a prescriber has selected the appropriate paediatric regimen.
| Active ingredient | Terbinafine |
|---|---|
| Drug class | Allylamine antifungal |
| Dosage form | Tablets |
| Available strengths | 250 mg |
| Route | Oral |
| Storage | Store at 25°C; excursions permitted between 15°C and 30°C. Protect from light and moisture, and keep the tablets in their original container. |
| ATC code | D01BA02 |
This product has 51 ratings, but only 5 written reviews so far. Share your experience and help other customers.
These terbinafine tablets used to cost a touch less, but honestly the quality still makes it worth paying for.
Delivery was spot on this time, though when I lived in London it used to arrive two or three days quicker for these terbinafine tablets.
I asked about storing the terbinafine tablets properly, and support gave me a clear, straightforward answer straightaway.
The terbinafine tablets came in secure inner packaging and arrived completely undamaged, which put my mind at ease.
I bought these terbinafine tablets for my father; they looked different in colour and shape from his usual pharmacy brand, but matching the active ingredient mattered more to us.
